Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05294367 · ClinicalTrials.gov registry record · Early Phase 1
Dietary and Topical Magnesium Replacement or Supplementation in Patients With Lymphoma
A Early Phase 1 study of Lymphoma, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT05294367: Recruiting Early Phase 1 study of Lymphoma, sponsored by Mayo Clinic.
NCT05294367 is a Early Phase 1 study of Lymphoma that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 60 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05294367, a Early Phase 1 study of Lymphoma, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
This early phase I trial investigates the effect of dietary and topical magnesium replacement on magnesium blood levels in patients with lymphoma. Magnesium is an element in the body that is important to cell health. The body cannot make magnesium and it typically comes from the food we eat. In patients who are ill, magnesium is often replaced intravenously (IV) through a vein or by mouth. This study may help researchers find out if being on a magnesium rich diet and using a magnesium lotion on the skin helps to keep magnesium blood levels in an ideal range. This study also investigates side effects and quality of life when receiving different forms of magnesium.
Primary Outcome
Will be defined as an increase in magnesium levels of at least 0.2 mg/dL from baseline level or an increase in magnesium level to 2.0 - 2.3 mg/dL at any time after the beginning of replacement.
Conditions Studied
Interventions
- OTHER Quality-of-Life Assessment
- DRUG Magnesium Chloride-based Lotion
- BEHAVIORAL Special Diet Therapy
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2022-04-15 |
| Est. Completion | 2027-04-01 |
| Phase | Early Phase 1 |
What NCT05294367 shows while recruiting
NCT05294367 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which Quality-of-Life Assessment is the first listed.
NCT05294367 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT05294367 about?
NCT05294367 is a clinical study titled "Dietary and Topical Magnesium Replacement or Supplementation in Patients With Lymphoma". This early phase I trial investigates the effect of dietary and topical magnesium replacement on magnesium blood levels in patients with lymphoma. Magnesium is an element in the body that is important to cell health. The body cannot make magnesium and it typically comes from the food we eat. In pati...
What is the current status of trial NCT05294367?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 60 participants. The study started on 2022-04-15. Estimated completion is 2027-04-01.
What conditions does trial NCT05294367 study?
This clinical trial studies the following conditions: Lymphoma.
What interventions are being tested in trial NCT05294367?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Magnesium Chloride-based Lotion (DRUG), Special Diet Therapy (BEHAVIORAL).
Who is sponsoring clinical trial NCT05294367?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05294367 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05294367's enrollment target sits among peer trials
60 129th of 299 higher than 163 of 299 other Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Exercise as an Immune Adjuvant for Allogeneic Cell Therapies
RECRUITING · Early Phase 1
-
Neuromodulation of Cardiovascular Risks Associated With Cardiotoxic Chemotherapy
RECRUITING · Early Phase 1
-
Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
RECRUITING · Early Phase 1
-
Neurotoxicity Prophylaxis With Intrathecal Dexamethasone and Simvastatin Post Axi-Cel
ACTIVE NOT RECRUITING · Early Phase 1
-
A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma
ACTIVE NOT RECRUITING · Early Phase 1
-
Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies
COMPLETED · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI